Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 701-705

  Venton, Geoffroy ^a   Ducournau, Aurelie ^a   Gross, Emmanuel ^a   Lechevallier, Eric ^a   Rochwerger, Alexandre ^a   Curvale, Georges ^a   Zink, Jean Vincent ^a   Salas, Sebastien ^a   Deville, Jean Laurent ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Clear cell renal carcinoma; Radiotherapy; Sunitinib

Indexed keywords

SUNITINIB; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE BIOPSY; BONE SCINTISCANNING; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; HUMAN; INFERIOR CAVA VEIN; KIDNEY CARCINOMA; KIDNEY TUMOR; KIDNEY VEIN; KNEE PAIN; METASTASIS; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THROMBECTOMY; TIBIA; VOMITING;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CHEMORADIOTHERAPY; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PALLIATIVE CARE; PYRROLES;

EID: 84856917319     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A and Moore N: Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111, 2007. (Pubitemid 350296300)
2. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ: Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271-2281, 2007. (Pubitemid 46849157)
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22): 3584-3590, 2009.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124, 2007. (Pubitemid 46089672)
5. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J and Small EJ: Phase III trial of bevacizumab plus interferon alpha versus interferon alpha monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13): 2137-2143, 2010.
6. Bukowski RM: Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. Curr Oncol Rep 11(2): 81-83, 2009.
7. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S and Rini BI: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8(11): 975-984, 2007. (Pubitemid 47629888)
8. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF and Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068, 2010.
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134, 2007. (Pubitemid 46089673)
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456, 2008.
11. Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S and Haanen J: Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4): 533-539, 2009.
12. Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS and Chung BI: Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol: 2011.
13. Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT and Kim HL: Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 184(3): 859-864, 2010.
14. Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC and Campbell SC: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2): 518-523; discussion 523, 2009.
15. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB and Boven E: Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14(8): 2431-2436, 2008. (Pubitemid 351551077)
16. Staehler M, Haseke N, Stadler T, Nuhn P, Roosen A, Stief CG and Wilkowski R: Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multikinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol, Epub 2010. PMID 20813555.
17. Taussky D and Soulieres D: Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect? Can J Urol 16(2): 4599-4600, 2009.
18. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS and George DJ: Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 5(4): 291-294, 2007. (Pubitemid 46867367)
19. Kirova YM, Servois V, Chargari C, Amessis M, Zerbib M and Beuzeboc P: Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy. Invest New Drugs, Epub 2010. PMID 21153752.
20. Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, Cindolo L, Novara G, Zigeuner RE, Bratti E, Tostain J, Altieri V, Abbou CC, Artibani W and Patard JJ: Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 104(5): 968-974, 2005. (Pubitemid 41170224)
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540, 1999. (Pubitemid 29368255)
22. Robert G, Gabbay G, Bram R, Wallerand H, Deminiere C, Cornells F, Bernhard JC, Ravaud A and Ballanger P: Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 55(6): 1477-1480, 2009.
23. Vaz MA, Pachon V, Grande E, Ferreiro R and Carrato A: Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma. Anticancer Drugs 22(8): 817-821, 2011.
24. Breau RH and Blute ML: Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5): 375-381, 2010.
25. Russo P: Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol 28(3): 295-301, 2010.
26. Russo P and O'Brien MF: Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35(4): 679-686; 2008.